Is Egrifta (Tesamorelin) Legal in Alabama? How to Access It Legally
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription drug, application BLA 022505, first approved November 10, 2010 [1]
- Current products / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), labels dated July 29, 2026 [2][3]
- Approved use / Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Dose / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; the two are not substitutable [2][3]
- Compounding / FDA has made no category-based statement about compounding tesamorelin [4][5][6]
- Sport / WADA prohibits tesamorelin at all times, in and out of competition [7]
What the federal status of tesamorelin is
Egrifta (tesamorelin acetate) was first approved on November 10, 2010, under application BLA 022505 [1]. Two labels are current: Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial, both dated July 29, 2026 [2][3].
The only approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label also states that long-term cardiovascular safety has not been established and that the drug is not indicated for weight loss management, having a weight-neutral effect [2].
Tesamorelin is a peptide analog of human growth hormone-releasing factor, not growth hormone itself. It binds GRF receptors on pituitary somatotroph cells and stimulates release of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [2].
Dosing differs by product and the two are not substitutable: Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily, and Egrifta WR is 1.28 mg (0.16 mL) once daily [2][3].
Access and use outside the label
Egrifta SV and Egrifta WR are FDA-approved prescription products [1][2][3]. FDA says that once a drug is approved, healthcare providers generally may prescribe it for an unapproved use when they judge it medically appropriate for that patient [8]. Use outside HIV lipodystrophy is outside the label for both products [2][3].
Questions worth asking
Branded Egrifta versus compounded tesamorelin
FDA's list of bulk substances that may present significant safety risks when compounded does not include tesamorelin, in the version dated April 22, 2026 [4]. It also appears in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [5][6]. FDA has made no category-based statement about compounding it.
Tesamorelin is not among the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [9][10]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [10].
Anti-doping status
WADA's Prohibited List names tesamorelin in S2.2.4, among growth hormone releasing factors, and prohibits it at all times, in and out of competition [7]. It is on the 2026 List and remains on the 2027 List in the tracked-changes version dated August 26, 2026 [7][11].
What the label says to watch for
Both labels contraindicate tesamorelin in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or the excipients, and pregnancy [2][3].
The labels direct prescribers to monitor IGF-1 and to consider discontinuing if it stays elevated, for example above 3 SDS; among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2]. The label says to evaluate glucose before and during therapy: HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% of placebo patients by week 26 [2]. The label also says to consider discontinuing in critically ill patients [2].
Frequently asked questions
What is the approved dose of Egrifta?
Is compounded tesamorelin legal?
Can tesamorelin be prescribed for a use outside HIV lipodystrophy?
What does the label say to monitor during treatment?
Is tesamorelin prohibited in sport?
References
Show all 11 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Understanding Unapproved Use of Approved Drugs "Off Label" | FDA.
- Official web page.
- Official web page.
- World Anti-Doping Agency.